Angiogenesis is frequent in non-small-cell lung cancer (nsclc) and is associated with more aggressive disease. Many clinical trials have evaluated the addition of antiangiogenic therapy to standard therapies for patients with nsclc. Bevacizumab, a monoclonal antibody directed against serum vascular endothelial growth factor, in combination with carboplatin-paclitaxel chemotherapy, has been shown to improve survival for patients with nsclc. However, bevacizumab-based therapy is not suitable for many nsclc patients, including those with squamous histology, poor performance status, brain metastases, and the presence of bleeding or thrombotic disorders. Similar efficacy has also been seen with carboplatin-pemetrexed followed by maintenance pemetrexed chemotherapy. In the second-line setting, the addition of ramucirumab to docetaxel-or the addition of bevacizumab to paclitaxel-has resulted in a modest improvement in efficacy, although the clinical importance of those findings is questionable. Many trials in nsclc have also evaluated oral antiangiogenic compounds, both in the first line in combination with chemotherapy and upon disease progression either as combination or single-agent therapy. No clear improvements in overall survival have been observed, although a subgroup analysis of a trial evaluating the addition of nintedanib to docetaxel showed improved survival that was limited to patients with adenocarcinoma. Those findings require validation, however.
INTRODUCTION
Angiogenesis-the formation of new blood vessels from pre-existing vessels 1 -is observed in many different cancers, including lung cancer 2 . The process depends on many activating and inhibiting factors that regulate angiogenesis and potentially influence the aggressiveness of cancer 3 . The most important factors associated with angiogenesis include vascular endothelial growth factor (vegf) 4, 5 , platelet-derived growth factor 6 , and fibroblast-derived growth factor 7 . Vascular endothelial cells depend for their survival on serum vegf, which stimulates proliferation and migration, inhibits apoptosis, and modulates endothelial permeability 8 . Antiangiogenic therapy aims to disrupt those processes by normalizing the abnormal vasculature in cancer, improving delivery of chemotherapy, enhancing its anti-vascular effect, and preventing rapid repopulation after systemic treatment.
APPROVED ANTIANGIOGENIC AGENTS IN FIRST-LINE THERAPY OF NON-SMALL-CELL LUNG CANCER Bevacizumab
Bevacizumab is a humanized monoclonal antibody that binds serum vegf, preventing its binding to and activation of vegf receptor 2 9 . Multiple trials (Table i) have evaluated bevacizumab in combination with platinum-based chemotherapy as initial therapy for advanced and metastatic non-small-cell lung cancer (nsclc).
The tolerability of bevacizumab in combination with chemotherapy in all subtypes of nsclc was established in a phase i trial 22 . However, a subsequent randomized phase ii trial of carboplatin-paclitaxel, with or without
The safety and efficacy of carboplatin-paclitaxel plus bevacizumab was also evaluated against a nonbevacizumab regimen of carboplatin-pemetrexed followed by maintenance pemetrexed (pronounce trial) 18 . No superiority was achieved in the primary endpoint of pfs without grade 4 toxicity or in the secondary outcomes of pfs, os, orr, or disease control rate.
One randomized phase ii trial evaluated the addition of bevacizumab to erlotinib in Japanese patients with EGFR mutation-positive nsclc 16 . A significant improvement in pfs was seen, but os data have not been reported. Randomized trials to validate those findings are ongoing, and at present, bevacizumab should not routinely be added to an egfr tyrosine kinase inhibitor (tki) in this population.
Examining the body of evidence, the addition of bevacizumab to carboplatin-paclitaxel chemotherapy improves os 23 . However, the benefits are modest, and the incremental toxicities are significant. Convincing evidence to support the addition of bevacizumab to other platinum-based chemotherapy is lacking. Decisions about treatment should reflect not only efficacy and toxicity, but also competing treatment strategies. Based on data from the pronounce trial, treatment with carboplatin-pemetrexed followed by maintenance pemetrexed represents an alternative to carboplatin-paclitaxel and bevacizumab, with similar efficacy and likely improved toxicity 18 .
OTHER ANTIANGIOGENIC AGENTS EVALUATED IN FIRST-LINE THERAPY FOR NSCLC Monoclonal Antibodies
Other monoclonal antibodies have been evaluated in combination with platinum-based chemotherapy as first-line therapy for advanced nsclc (Table i) .
Ramucirumab is a human immunoglobulin G monoclonal antibody that specifically binds to the extracellular domain of vegf receptor 2, blocking binding of the vegf ligand to that receptor 24 . Promising data were observed in a single-arm phase ii trial of ramucirumab in combination with carboplatin-paclitaxel 19 . A randomized phase ii trial compared the addition of ramucirumab to pemetrexed-cisplatin or pemetrexed-carboplatin, followed by maintenance pemetrexed, with chemotherapy alone 20 . The trial did not meet its primary endpoint of improved pfs. However, the observed pfs (7.2 months vs. 5.6 months) and orr (49% vs. 38%) both favoured the addition of ramucirumab. The most common adverse events were thrombocytopenia, neutropenia, fatigue, anemia, nausea, back pain, and hypertension.
Aflibercept is a recombinant fusion protein, consisting of the extracellular domain of the human vegf receptor (vegfr), fused to the hinge region of the human immunoglobulin G1 Fc domain 25 . Commonly called "vegf trap," it binds all isoforms of serum vegf, vegf-b, and human placental growth factor. The addition of aflibercept to cisplatin-pemetrexed did not appear to improve efficacy in a trial of untreated patients with nsclc 21 . The trial was closed early because of 3 confirmed cases of reversible posterior leucoencephalopathy syndrome.
Neither ramucirumab or aflibercept are used in the first-line management of nsclc. 
TKIs
Multiple trials in patients with advanced nsclc have evaluated the addition of oral tkis with antiangiogenic activity to platinum-based chemotherapy (Table ii) . However, no such tki has demonstrated a clear improvement in efficacy, and many have added considerable toxicity to standard platinum-based chemotherapy regimens. Axitinib, an oral potent and selective vegfr tki showed preclinical antitumour efficacy in combination with chemotherapy agents in multiple tumour models 34 . A randomized phase ii trial evaluated cisplatin-pemetrexed alone or in combination with two dose schedules of axitinib 26 . Patients in both axitinib arms experienced a higher response rate, but no significant difference in pfs or os. A second randomized phase ii trial compared carboplatin-paclitaxel plus bevacizumab with carboplatin-paclitaxel plus axitinib 27 . There was no statistically significant difference in efficacy between the treatments, and axitinib was less well-tolerated, resulting in more temporary discontinuations and dose reductions because of side effects. Axitinib remains investigational as a treatment for nsclc. Similar findings have been observed with other oral vegf inhibitors such as cediranib and motesanib. Despite promising data from phase i trials, the addition of cediranib (30-45 mg daily) to carboplatin-paclitaxel resulted in considerably increased toxicity necessitating dose reductions 28, 29 . Some increased activity was observed at higher doses, but cediranib 20 mg daily failed to improve pfs or os 29 . The addition of motesanib to carboplatinpaclitaxel resulted in an increased risk of death and serious hemoptysis for patients with squamous histology 30 . The final analysis conducted in patients with nonsquamous histology showed improvements in pfs and orr for patients randomized to chemotherapy plus motesanib. However, those improvements did not translate to improvement in os. In the trial, increased toxicity was associated with motesanib, including higher incidences of neutropenia, gastrointestinal events, hypertension, pneumonia, cholecystitis, and gallbladder-related disorders.
Several multi-targeted tkis have been evaluated in combination with first-line platinum-based chemotherapy. Sorafenib, a potent inhibitor of several receptor tyrosine kinases-including braf, vegfr-2, vegfr-3, pdgfr, c-Kit, and Flt-3-has been evaluated in two large randomized trials. The escape trial evaluated the addition of sorafenib to carboplatin-paclitaxel 31 . Patients with disease of all histologic subtypes were included. The trial, which was stopped early for futility, failed to show any improvement in os (10.7 months vs. 10.6 months; hr: 1.15; 95% ci: 0.94 to 1.41). A subgroup analysis showed a shorter median os in patients with squamous-cell carcinoma randomized to sorafenib plus chemotherapy compared with chemotherapy alone (8.9 months vs. 13.9 months; hr: 1.85; 95% ci: 1.22 to 2.81). The incidence of drug-related adverse events was higher in patients receiving sorafenib. The most common adverse events were thrombocytopenia, rash, desquamation, hand-foot syndrome, pruritus, and hypertension. Similarly, in the nexus trial (limited to patients with nonsquamous nsclc), there was no improvement in the primary endpoint of os 32 . The toxicity profile was similar to that seen in the escape trial.
Trials evaluating vandetanib, a dual vegfr and egfr tki, have also failed to improve treatment outcomes for patients with advanced nsclc 33 . A randomized phase ii trial of vandetanib alone or carboplatin-paclitaxel with or without vandetanib did not show an improvement in os. The pfs for carboplatin-paclitaxel alone or in combination with vandetanib was similar, and vandetanib monotherapy was inferior to carboplatin-paclitaxel.
It is unclear why, in comparison with bevacizumab, which has resulted in modest improvements in os, oral antiangiogenic agents have not improved treatment efficacy in advanced nsclc. Improvements in some measures of efficacy, such as orr and pfs, have been observed with some agents. However, increased toxicities have often precluded the administration of those agents at full dose. Currently, no approved oral antiangiogenic agents have been recommended as first-line therapy in advanced nsclc.
APPROVED ANTIANGIOGENIC AGENTS AFTER PROGRESSION ON PLATINUM-BASED THERAPY
Antiangiogenic therapies have been extensively evaluated, either alone or in combination with other systemic therapies, in patients with nsclc progressing after initial platinum-based therapy. Monoclonal antibodies including bevacizumab and ramucirumab, as well as receptor tkis, have demonstrated some activity in this setting, although clinical practice has not been extensively modified at this time.
Bevacizumab
Multiple trials have evaluated bevacizumab in the secondline setting (Table iii) . The phase iii ultimate trial randomized 166 patients with advanced nsclc progressing after first-line or second-line therapy 2:1 to weekly paclitaxel (90 kg/m 2 ) on days 1, 8, and 15 in combination with bevacizumab 10 mg/kg on days 1 and 15 every 4 weeks or to intravenous docetaxel monotherapy 75 mg/m 2 on a 3-week cycle 37 . Median follow-up was 28.9 months. The primary outcome, pfs, was significantly improved for patients randomized to paclitaxel-bevacizumab compared with those randomized to docetaxel (5.4 months vs. 3.9 months; hr: 0.62; 95% ci: 0.44 to 0.87). Furthermore, a significant improvement in the orr in favour of the combination therapy was noted (22.5% vs. 5.5%, p = 0.006). However, no differences in os were observed between the two groups (9.9 months vs. 11.4 months; hr: 1.18; 95% ci: 0.81 to 1.72). Weekly paclitaxel-bevacizumab was associated with less neutropenia, but more neuropathy and hypertension. Although the primary outcome was significantly improved in this study, the lack of improvement in os limits the clinical importance of these data.
Additional trials examined bevacizumab in combination with erlotinib or with chemotherapy. Herbst et al. randomized patients to chemotherapy alone or to chemotherapy or erlotinib in combination with bevacizumab 35 . The addition of bevacizumab resulted in numerically higher orr, pfs, and os-findings that were not confirmed in a phase iii trial. The beta trial compared erlotinib and bevacizumab 15 mg/kg with erlotinib and placebo after progression on first-line therapy 36 . The primary endpoint in the study, os, was not significantly improved (9.3 months vs. 9.2 months; hr: 0.97; 95% ci: 0.80 to 1.18). However, significant improvements were observed in the secondary endpoints of pfs (3.4 months vs. 1.7 months) and orr (13% vs. 6%). Based on that evidence, the data are insufficient to recommend the combination of erlotinib and bevacizumab. The role of bevacizumab in second-line therapy for patients who received bevacizumab in the first-line setting is also unclear. The avaall trial randomized patients with nsclc progressing on first-line platinum doublet and bevacizumab therapy to continue bevacizumab with chemotherapy or to receive chemotherapy alone 40 . The results of the trial were presented at the 2017 American Society of Clinical Oncology annual meeting. Patients randomized to continue bevacizumab experienced longer os; however, the difference was not statistically significant (11.9 months vs. 10.2 months; hr: 0.84; 90% ci: 0.71 to 1.0). Similarly, no significant increase in pfs was observed.
Much as in first-line therapy, the addition of bevacizumab in second-line therapy was associated with an improvement in the intermediate outcomes of pfs and orr. Why those improvements fail to translate into an improvement in os is unclear. One argument is that significant crossover to bevacizumab occurred in the ultimate trial. Although the reported gains in efficacy could be important to some physicians and patients, they are generally not favourable from a cost-effectiveness standpoint. Second-line therapy with bevacizumab has not affected practice in the Canadian environment.
Ramucirumab
The revel trial randomized 1253 patients (all nsclc histologies) to docetaxel 75 mg/m 2 plus ramucirumab 10 mg/kg or to docetaxel 75 mg/m 2 plus placebo 38 . The addition of ramucirumab to docetaxel was associated with a significant improvement in pfs (4.5 months vs. 3.0 months; hr: 0.76; 95% ci: 0.68 to 0.86) and in os (10.5 months vs. 9.1 months; hr: 0.86; 95% ci: 0.75 to 0.98). The improvement in os was observed for all histologic subtypes. Compared with patients receiving docetaxel alone, those receiving the combination therapy experienced more grade 3 or greater adverse events (49% vs. 40%). The increase in toxicities included febrile neutropenia (16% vs. 10%), neutropenia (49% vs. 40%), leucopenia (14% vs. 12%), and hypertension (6% vs. 2%). However, death from adverse events did not differ between the groups (5% vs. 6%). Although ramucirumab has been approved by the U.S. Food and Drug Administration, the improvement in os is modest, such that a consideration of cost-effectiveness is important in the decision to give it. Alternative treatment strategies with immune checkpoint inhibitors likely offer greater benefit and should also be considered for this population 41 .
Nintedanib
Nintedanib is a multi-targeted antiangiogenic agent with sites of inhibition including vegfr, platelet-derived growth factor receptor, and fibroblast-derived growth factor receptor. It has been evaluated in combination with docetaxel or pemetrexed in two large phase iii randomized trials 42, 43 . The first of those trials, lume-Lung 2, was conducted exclusively in patients with nsclc of nonsquamous histology 42 . In the lume-Lung 1 trial, docetaxel plus nintedanib was compared with docetaxel plus placebo in all nsclc histologic subtypes 43 . Compared with patients randomized to docetaxel alone, those randomized to docetaxel plus nintedanib experienced a significantly improved pfs (3.4 months vs. 2.7 months; hr: 0.85; 95% ci: 0.75 to 0.96), which was the primary outcome. A modified hierarchical analysis for os was pre-specified to examine os in patients with adenocarcinoma who progressed within 9 months of commencing first-line therapy, then in all patients with adenocarcinoma, and finally in the overall intention-to-treat population. Significant improvements in os were seen in patients randomized to docetaxel plus nintedanib, in those with adenocarcinoma progressing within 9 months (10.9 months vs. 7.9 months), and in the entire adenocarcinoma subset (12.6 months vs. 10.3 months). No improvement in os was seen in the analysis of the overall study population. Nevertheless, the first two os analyses represent nonrandomized comparisons.
Patient-reported outcomes were also assessed in lume-Lung 1. No differences were observed in time to deterioration in global health status or in common lung cancer symptoms of cough, dyspnea, or pain 44 . Multiple post-hoc analyses of the data have been conducted to try to better define the patient population who might benefit from the addition of nintedanib 45 , but those analyses are all just hypothesis-generating.
The lume-Columbus trial was designed to verify the findings from lume-Lung 1 in patients with adenocarcinoma progressing after first-line therapy; however, that trial was discontinued. The findings in lume-Lung 1 and 2 were inconsistent for patients with adenocarcinoma. Nintedanib was approved for use in nsclc by the European Medicines Agency, but not by the U.S. Food and Drug Administration or Health Canada. The benefit of nintedanib in the second-line therapy of advanced nsclc therefore remains unclear.
OTHER ANTIANGIOGENIC AGENTS NOT APPROVED IN NSCLC
Multiple additional antiangiogenic agents have been tested in the second-line therapy of nsclc. Those agents include drugs that specifically target the vegf pathway (aflibercept) and multi-targeted tyrosine kinase inhibitors that could target a combination of vegfr, egfr, mesenchymal-to-epithelial transition, platelet-derived growth factor receptor, and other receptors (cabozantinib, sunitinib, sorafenib). Table iv presents findings from the relevant clinical trials for those drugs.
Resistance to agents that block only vegfr can be mediated through pathways such as mesenchymal-toepithelial transition because its ligand, hepatocyte growth factor, can synergistically activate vegfr. Cabozantinib, a multi-targeted tyrosine kinase inhibitor, might overcome a potential mechanism of resistance to vegfr therapy through blockade of both mesenchymal-to-epithelial transition and vegfr. Some efficacy of cabozantinib was observed in a phase ii randomized discontinuation trial 46 . All the patients, who had previously been heavily treated, were given cabozantinib for 12 weeks. At that point, they were randomized to continue on the drug or to switch to placebo. At 12 weeks, the response rate was 10%, and the pfs was 4.2 months. Data for the full randomized cohort were not available.
Recently, data from the ecog 1512 randomized phase ii trial comparing erlotinib alone, cabozantinib alone, and the combination erlotinib-cabozantinib in patients with previously treated egfr wild-type nsclc were published 47 . Greater efficacy was seen in both groups of patients treated with cabozantinib. Longer pfs was observed in patients receiving cabozantinib alone (4.3 months; hr: 0.39; 80% ci: 0.27 to 0.55) and erlotinib-cabozantinib (4.7 months; hr: 0.37; 80% ci: 0.25 to 0.53) than in those receiving erlotinib alone (1.8 months). Similarly, os was longer in patients randomized to cabozantinib alone (9.2 months; hr: 0.68; 80% ci: 0.49 to 0.95) or to cabozantinib-erlotinib (13.3 months; hr: 0.51; 80% ci: 0.35 to 0.74) than in those randomized to erlotinib alone (5.1 months). Those results appear promising, but require confirmation in a phase iii trial.
Multiple studies have assessed the utility of sunitinib in the second-line setting, observing no clear improvement in efficacy. A worse os appeared to be associated with sunitinib-pemetrexed than with pemetrexed alone (hr: 2.0; 95% ci: 1.2 to 3.2) 50 . Two additional trials investigated the combination sunitinib-erlotinib in patients with previously treated nsclc 48, 49 . The pfs findings in those trials were discordant, and no improvement in os was observed in either trial. Notably, quality of life as measured by the EQ-5D (EuroQol Research Foundation, Rotterdam, Netherlands) showed no improvement. Sunitinib does not appear to have a role as an antiangiogenic therapy in nsclc.
Multiple trials have also investigated the role of sorafenib in the second line and beyond. Sorafenib was studied in a randomized discontinuation trial in 299 patients who had progressed on at least 2 prior lines of chemotherapy and an egfr-targeted therapy 53 . Patients received 2 months of oral sorafenib 400 mg twice daily. If a response was observed, patients would continue on treatment; those experiencing progression discontinued therapy. The remaining patients, those with stable disease (n = 105), were randomized to continue or discontinue therapy. An improvement in pfs was observed for the patients randomized to sorafenib (3.3 months vs. 2.0 months; hr: 0.51; 95% ci: 0.30 to 0.87). However, that improvement did not translate into an improvement in os (13.7 months vs. 9.0 months; hr: 0.67; 95% ci: 0.40 to 1.11). Interpreting the findings of the study requires caution, because an error in patient randomization occurred. Initially, 8 patients randomized to the sorafenib arm received a placebo, and 12 patients on the placebo arm received sorafenib.
Sorafenib has also been studied in combination with pemetrexed and erlotinib. The Lun 160 trial used a 2:1 randomization protocol in comparing erlotinib-sorafenib with erlotinib-placebo in patients after failure of 1 or 2 Not assessed.
Not assessed.
Not assessed. 54 . Despite some evidence of activity in the second-line setting, sorafenib alone or in combination with other agents has no clear role in nsclc.
Four trials-zeal, zodiac, zest, zephyr-have investigated the role of vandetanib in the second-line setting ( Table iv) . None of the trials showed any improvement in os. In zeal, 534 patients with nsclc were randomized to pemetrexed plus placebo or pemetrexed plus oral vandetanib 100 mg once daily 56 . Despite an improved orr (19% vs. 8%, p < 0.001), the pfs (17.6 weeks vs. 11.9 weeks; hr: 0.86; 95% ci: 0.69 to 1.06) and os (10.5 months vs. 9.2 months; hr: 0.86; 95% ci: 0.65 to 1.13) were not significantly improved. However, a delayed time to decline of lung cancer symptoms as assessed by the Lung Cancer Symptom Scale was demonstrated in the combination arm.
In zodiac, 1391 patients were randomized to docetaxel alone or to docetaxel plus vandetanib 55 . An improvement in pfs was observed (4.0 months vs. 3.2 months; hr: 0.79; 95% ci: 0.70 to 0.90), but did not translate into an improved os (10.6 months vs. 10 months; hr: 0.91; 95% ci: 0.78 to 1.07). As in zeal, the time to decline of lung cancer-related symptoms favoured the combination arm.
In zest, a study designed to assess superiority, 1240 patients who had received at least 1 or 2 lines of prior chemotherapy were randomized to oral vandetanib 300 mg daily or to oral erlotinib 150 mg once daily 57 . The overall results of the trial were negative, with no improvement seen in pfs (2.6 months vs. 2.0 months; hr: 0.98; 95% ci: 0.87 to 1.10), os (6.9 months vs. 7.8 months; hr: 1.01; 95% ci: 0.89 to 1.16), or the time to decline of lung cancer-related symptoms per the 30-question core Quality of Life Questionnaire from the European Organisation for Research and Treatment of Cancer and the associated LCS13 module for patients with lung cancer.
Lastly, in zephyr, 924 patients who had received chemotherapy as well as egfr-targeted therapy were randomized 2:1 to oral vandetanib 300 mg once daily or to placebo 58 . As in many of the trials in this setting, a small benefit in pfs was observed (1.9 months vs. 1.8 months; hr: 0.63; 95% ci: 0.54 to 0.74), but no improvement in os was demonstrated (8.5 months vs. 7.8 months; hr: 0.95; 95% ci: 0.8 to 1.11). Furthermore, no difference was noted in lung cancer-related symptoms, as identified by the Functional Assessment of Cancer Therapy-Lung (FACIT.org, Elmhurst, IL, U.S.A.). The body of evidence evaluating vandetanib fails to show any clear benefit for its use in previously treated patients with advanced nsclc.
SUMMARY
Targeting angiogenesis remains an important therapeutic strategy in the management of some solid-organ malignancies such as colon cancer. However, the utility of the approach in nsclc has not been as clearly established. The addition of bevacizumab to platinum-based chemotherapy in the first-line setting carries a modest benefit, although competing non-bevacizumab strategies are available. Some antiangiogenic therapies have been approved in the second line by the U.S. Food and Drug Administration (bevacizumab, ramucirumab) and the European Medicines Agency (nintedanib), but the extent of the improvements in pfs and os are modest and must be balanced against the expected toxicities and the costs associated with those agents. Furthermore, with the emergence of randomized data showing the efficacy of immunotherapy in both the first and second lines, and improvements in treatment options for molecularly driven nsclc (EGFR, ROS1, ALK, and so on), the utility of antiangiogenic therapies in the second-line setting in the management of patients with nsclc might be limited.
